Skip to content
Disclosery

Patient Square Capital LP

Follow

13F filer, CIK 1819257, MENLO PARK, CA

Patient Square Capital LP reported $645,523,811 across 23 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-12. Its ten largest share positions make up 80.13% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001819257-26-000005

Period
2026-06-30
Reported value
$646M
Holdings
23
Top 10 weight
80.13%
New
6
Sold out
12

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RVMDnew+276,000$51.7M
UTHRnew+37,120$20.1M
BNTXnew+134,429$12.5M
ABVXadded+85,255$11.4M
CCCCnew+1,608,815$7.51M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
INSMexited-157,500-$25.8M
LEGNexited-990,000-$17.9M
NKTRexited-210,000-$15.1M
ARGXreduced-13,718-$12.7M
CELCexited-95,000-$10.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001819257-26-000005, largest first. % of portfolio is the value over $645,523,811, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 12,228,465 shares; 2024Q4: 12,480,000 shares; 2025Q1: 12,480,000 shares; 2025Q2: 12,480,000 shares; 2025Q3: 12,480,000 shares; 2025Q4: 8,166,047 shares; 2026Q1: 8,166,047 shares; 2026Q2: 8,020,928 shares 8,020,928$284M43.97%-145,119Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 276,000 shares 276,000$51.7M8.01%newTimeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 64,900 shares; 2025Q1: 116,362 shares; 2025Q2: 113,462 shares; 2025Q3: 104,262 shares; 2025Q4: 298,682 shares; 2026Q1: 230,000 shares; 2026Q2: 260,500 shares 260,500$30.5M4.72%+30,500Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 151,833 shares; 2025Q4: 130,000 shares; 2026Q1: 121,245 shares; 2026Q2: 206,500 shares 206,500$27.5M4.26%+85,255Timeline
ONCBEONE MEDICINES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 69,312 shares; 2026Q1: 80,542 shares; 2026Q2: 90,020 shares 90,020$25.7M3.97%+9,478Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 242,341 shares; 2024Q4: 207,603 shares; 2025Q1: 245,496 shares; 2025Q2: 244,283 shares; 2025Q3: 345,381 shares; 2025Q4: 542,696 shares; 2026Q1: 493,000 shares; 2026Q2: 671,209 shares 671,209$23.2M3.6%+178,209Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 29,000 shares; 2025Q3: 15,500 shares; 2025Q4: 26,000 shares; 2026Q1: 36,718 shares; 2026Q2: 23,000 shares 23,000$21.3M3.31%-13,718Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 37,120 shares 37,120$20.1M3.12%newTimeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 116,684 shares; 2026Q2: 110,000 shares 110,000$16.9M2.62%-6,684Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 317,372 shares; 2026Q1: 596,000 shares; 2026Q2: 425,000 shares 425,000$16.4M2.55%-171,000Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 359,050 shares; 2026Q1: 693,534 shares; 2026Q2: 909,474 shares 909,474$14.9M2.31%+215,940Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 136,500 shares; 2026Q1: 227,000 shares; 2026Q2: 220,000 shares 220,000$13.3M2.06%-7,000Timeline
BNTXBIONTECH SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 134,429 shares 134,429$12.5M1.94%newTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 170,000 shares; 2026Q1: 195,000 shares; 2026Q2: 355,800 shares 355,800$11M1.7%+160,800Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 90,572 shares; 2024Q4: 224,038 shares; 2025Q1: 253,838 shares; 2025Q2: 245,838 shares; 2025Q3: 250,838 shares; 2025Q4: 308,141 shares; 2026Q1: 200,000 shares; 2026Q2: 212,500 shares 212,500$10.8M1.67%+12,500Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 125,000 shares; 2025Q4: 150,000 shares; 2026Q1: 93,882 shares; 2026Q2: 108,000 shares 108,000$10.5M1.63%+14,118Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 1,489,909 shares; 2025Q1: 2,368,186 shares; 2025Q2: 2,635,000 shares; 2025Q3: 2,981,396 shares; 2025Q4: 4,963,756 shares; 2026Q1: 3,450,000 shares; 2026Q2: 5,050,000 shares 5,050,000$10.5M1.63%+1,600,000Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,361,979 shares; 2024Q4: 1,410,331 shares; 2025Q1: 1,481,977 shares; 2025Q2: 1,352,837 shares; 2025Q3: 1,011,839 shares; 2025Q4: 780,000 shares; 2026Q1: 795,000 shares; 2026Q2: 720,000 shares 720,000$10.3M1.59%-75,000Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 210,000 shares; 2026Q1: 400,645 shares; 2026Q2: 370,000 shares 370,000$9.7M1.5%-30,645Timeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,608,815 shares 1,608,815$7.51M1.16%newTimeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,967,171 shares 1,967,171$7.44M1.15%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 142,201 shares; 2025Q2: 140,000 shares; 2025Q3: 92,592 shares; 2025Q4: 139,000 shares; 2026Q1: 100,000 shares; 2026Q2: 47,500 shares 47,500$5.45M0.84%-52,500Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 175,050 shares 175,050$4.38M0.68%newTimeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
INSMINSMED INC157,500$25.8Mshares
LEGNLEGEND BIOTECH CORP990,000$17.9Mshares
NKTRNEKTAR THERAPEUTICS210,000$15.1Mshares
CELCCELCUITY INC95,000$10.8Mshares
MRKMERCK & CO INC80,000$9.62Mshares
CATXPERSPECTIVE THERAPEUTICS INC1,625,000$6.78Mshares
DFTXDEFINIUM THERAPEUTICS INC331,000$6.26Mshares
HROWHARROW INC165,209$5.83Mshares
TARAPROTARA THERAPEUTICS INC1,030,846$5.37Mshares
CTMXCYTOMX THERAPEUTICS INC.1,085,790$5.1Mshares
ASMBASSEMBLY BIOSCIENCES INC136,315$3.78Mshares
SYRESPYRE THERAPEUTICS INC1,000$50.4Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001819257-26-000005 base2026-08-12acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001819257-26-000005 Quarter ended 2026-06-302026-08-12acceptance time not in the bulk data set
13F-HR 0001819257-26-000003 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001819257-26-000002 Quarter ended 2025-12-312026-02-12acceptance time not in the bulk data set
13F-HR 0001819257-25-000002 Quarter ended 2025-09-302025-11-10acceptance time not in the bulk data set
13F-HR 0000950123-25-007478 Quarter ended 2025-06-302025-08-11acceptance time not in the bulk data set
13F-HR 0000950123-25-005195 Quarter ended 2025-03-312025-05-14acceptance time not in the bulk data set
13F-HR 0000950123-25-002377 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0000950123-24-011804 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0000950123-24-007977 Quarter ended 2024-06-302024-08-13acceptance time not in the bulk data set
13F-HR 0000950123-24-005073 Quarter ended 2024-03-312024-05-14acceptance time not in the bulk data set
13F-HR 0000950123-24-001861 Quarter ended 2023-12-312024-02-13acceptance time not in the bulk data set
13F-HR 0000950123-23-010496 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0000950123-23-007492 Quarter ended 2023-06-302023-08-11acceptance time not in the bulk data set
13F-HR 0000950123-23-004214 Quarter ended 2023-03-312023-05-10acceptance time not in the bulk data set
13F-HR 0000950123-23-001941 Quarter ended 2022-12-312023-02-13acceptance time not in the bulk data set